| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Articles in PresS, published online ahead of print May 7, 2002
Am J Physiol Heart Circ Physiol, 10.1152/ajpheart.00185.2002
Submitted on March 4, 2002
Accepted on May 1, 2002
1 University of British Columbia, St. Paul's Hospital, McDonald Research Laboratory and iCAPTURE Centre, Vancouver, BC, Canada
* To whom correspondence should be addressed. E-mail: svaneeden{at}mrl.ubc.ca.
Interleukin-6 (IL-6) shortens the transit time of polymorphonuclear leukocyte (PMN) through the marrow and accelerates their release into the circulation. In contrast to other inflammatory stimuli, this response is associated with a decrease in L-selectin levels on circulating PMN. The present study was designed to determine the effect of IL-6 on L-selectin levels of PMN in rabbits. Recombinant human IL-6 (2 µg/kg) caused a decrease in L-selectin levels on circulating PMN 3-12 hours after treatment (p<0.05). L-selectin levels decreased on PMN already in the circulation for up to 4 hours (p<0.05), on PMN released from the marrow post-treatment for up to 12 hours (p<0.01) and on PMN in the marrow for up to 6 hours (p<0.05) following IL-6 treatment. We conclude that IL-6 decreases L-selectin levels on circulating PMN by 1) demarginating PMN with low levels of L-selectin and 2) releasing PMN from the marrow with low levels of L-selectin. We postulate that this prolonged down-regulation of L-selectin on circulating PMN could influence their recruitment into inflammatory sites.
This article has been cited by other articles:
|
|
 |
|
  J.-M. Dayer and E. Choy Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor Rheumatology, October 23, 2009; (2009) kep329v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Barnes and B. R. Celli Systemic manifestations and comorbidities of COPD Eur. Respir. J., May 1, 2009; 33(5): 1165 - 1185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Emery, E Keystone, H P Tony, A Cantagrel, R van Vollenhoven, A Sanchez, E Alecock, J Lee, and J Kremer IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial Ann Rheum Dis, November 1, 2008; 67(11): 1516 - 1523. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Kielar, R. John, M. Bennett, J. A. Richardson, J. M. Shelton, L. Chen, D. R. Jeyarajah, X. J. Zhou, H. Zhou, B. Chiquett, et al. Maladaptive Role of IL-6 in Ischemic Acute Renal Failure J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3315 - 3325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. U. Gurkan, C. O'Donnell, R. Brower, E. Ruckdeschel, and P. M. Becker Differential effects of mechanical ventilatory strategy on lung injury and systemic organ inflammation in mice Am J Physiol Lung Cell Mol Physiol, September 1, 2003; 285(3): L710 - L718. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
